You are here: Industry Insights > VIII

News List

U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Adult Prophylactic Use of VONVENDI [von Willebrand factor (Recombinant)] firstwordpharma
June 15, 2021
Takeda Pharmaceutical Company Limited announced today that FDA has accepted for review the sBLA) for VONVENDI® [von Willebrand factor (Recombinant)] for prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults.
Gene Therapy May Be Long-Term Cure for Type of Hemophilia drugs
January 03, 2020
A new gene therapy appears to serve as a functional cure for the most common type of hemophilia, early clinical trial results indicate.
Hemlibra shows "clinically meaningful" bleed control in paediatric haemophilia A patients pharmafile
December 07, 2018
In another reveal at the American Society of Hematology (ASH) Annual Meeting 2018, Roche unveiled new Phase 3 findings for Hemlibra (emicizumab) as a prophylactic in haemophilia A patients
Bayer's Jivi approved in Europe for previously treated haemophilia A pharmafile
November 29, 2018
Bayer has revealed that its recombinant Factor VIII (rFVIII) replacement therapy Jivi, also known as BAY94-9027, has received approval from the European Commission for the treatment...
FDA expands indication of Roche's Hemlibra in haemophilia pharmafile
November 20, 2018
The FDA has chosen to expand the label of Roche’s Hemlibra (emicizumab-kxwh), approving it for routine prophylaxis to prevent the frequency